AI Shows Promise in Decision-Making Diagnostics for Liver Disease

Study highlights AI’s growing role in enhancing diagnostic accuracy for conditions like metabolic-associated steatotic liver disease (MASLD).

The application of artificial intelligence (AI) in healthcare continues to expand, with a new study demonstrating its potential to improve diagnostic accuracy for metabolic-associated steatotic liver disease (MASLD). Presented at The Liver Meeting, hosted by the American Association for the Study of Liver Diseases, the study highlights how AI-driven algorithms can address challenges in identifying patients with early-stage liver disease.

Dr Ariana Stuart, lead author and resident at the University of Washington, emphasised the need for innovation in diagnostics, stating: “A significant proportion of patients who meet criteria for MASLD go undiagnosed. This is concerning because delays in early diagnosis increase the likelihood of progression to advanced liver disease.”

The study analysed electronic health records (EHRs) from three sites within the University of Washington Medical System. An AI algorithm reviewed imaging findings to identify cases of MASLD, a common condition linked to obesity, Type-2 diabetes, and abnormal cholesterol levels. Of the 834 patients who met the criteria, only 137 had been officially diagnosed, revealing an 83% gap in recognition despite clear data in their records.

A Complement to Clinical Expertise

AI’s integration into diagnostics reflects an effort to enhance, rather than replace, traditional medical practices. Dr Stuart noted, “People should not interpret our findings as a lack of primary care training or management. Instead, our study shows how AI can complement physician workflow to address the limitations of traditional clinical practice.”

By identifying patterns and insights in large datasets, AI can help clinicians flag potential cases that might otherwise be missed. This is particularly valuable for MASLD, which often remains asymptomatic in its early stages, complicating efforts to diagnose and intervene.

MASLD is the most common form of liver disease, affecting millions worldwide. Left untreated, it can progress to more severe liver conditions. The study demonstrates how AI-powered tools can assist in early detection, reducing the risk of progression and improving patient outcomes.

Growing Role for AI in Decision Support

This research underscores a broader trend: the increasing use of AI in decision-making diagnostics. From radiology to oncology and now hepatology, AI is proving its utility in analysing complex medical data with speed and accuracy. The implications are significant, particularly for healthcare systems facing increasing demands and limited resources.

For MASLD, where diagnostic delays can have serious consequences, AI’s role could be transformative. The study provides a roadmap for incorporating AI into clinical workflows, addressing unmet needs in early detection and ensuring that patients receive timely care.

While challenges remain, such as ensuring the ethical use of patient data and integrating these tools seamlessly into healthcare settings, the potential benefits are clear. AI in diagnostics is not just a technological advance but a shift towards more precise, efficient, and data-driven care.

As AI applications continue to be tested and refined, they are setting a new standard in decision support for clinicians. This latest study demonstrates how technology can fill gaps in traditional diagnostics, paving the way for wider adoption of AI in medical practice.